Pazopanib
Treatment for Kidney Cancer
Typical Dosage: 800 mg oral once daily
Effectiveness
60%
Safety Score
40%
Clinical Trials
100
Participants
1.5K
Comparative Safety Scale(Higher is safer)
Cyanideโ ๏ธ
Meth๐
Cigarettes๐ฌ
Chemoโข๏ธ
Alcohol๐บ
Morphine๐
Antibiotics๐
Tylenol๐
Exercise๐
Water๐ง
40
DangerousModerateSafe
Treatment Details
Dosage Range
800 mg oral once daily
Time to Effect
Weeks to months
Treatment Duration
Until disease progression or unacceptable toxicity
Evidence Quality
HIGHConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$130,000
Monitoring:$15,000
Side Effect Mgmt:$10,000
Total Annual:$155,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$93,485/QALY
QALYs Gained
0.8
Outcome-Based Costs
Cost per Responder
$516,667
Cost per Remission
$5,166,667
Comparison vs Sunitinib
Cost Difference
+$10,000/year
More expensive
QALY Difference
0.00 QALYs
Same outcomes
Dominance
No dominance
Pazopanib Outcomes
for Kidney Cancer
Efficacy Outcomes
Overall Effectiveness
+60%
Response Rate
+30%
Remission Rate
+3%
Common Side Effects
Diarrhea
+52%
Hair color changes
+39%
Nausea
+26%
Fatigue
+26%
Hypertension
+25%
Decreased appetite
+22%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
18 completed trials for Pazopanib in Kidney Cancer
Rotating Pazopanib and Everolimus to Avoid Resistance
NCT01408004COMPLETEDPHASE2
101 participants
INTERVENTIONAL
Rotterdam, Netherlands +16 more
Started: Nov 1, 2011
Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034
NCT00478725COMPLETEDPHASE1
10 participants
INTERVENTIONAL
Minneapolis, United States +1 more
Started: Jul 18, 2007
Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma
NCT00256880COMPLETEDPHASE2
100 participants
INTERVENTIONAL
Little Rock, United States +7 more
Started: Jan 1, 2005
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
NCT00244764COMPLETEDPHASE2
225 participants
INTERVENTIONAL
Duarte, United States +44 more
Started: Oct 1, 2005
Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma
NCT01649778COMPLETED
662 participants
OBSERVATIONAL
Phoenix, United States +143 more
Started: Jul 19, 2012
Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma
NCT00334282COMPLETEDPHASE3
435 participants
INTERVENTIONAL
Capital Federal, Argentina +98 more
Started: Apr 1, 2006
Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer
NCT00387764COMPLETEDPHASE3
80 participants
INTERVENTIONAL
Capital Federal, Argentina +57 more
Started: Sep 1, 2006
A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients
NCT00363194COMPLETEDPHASE1
28 participants
INTERVENTIONAL
Indianapolis, United States +1 more
Started: Sep 21, 2006
Study To Assess Long Term Safety Of Pazopanib
NCT00387205COMPLETEDPHASE1
188 participants
INTERVENTIONAL
Duarte, United States +18 more
Started: Jun 20, 2006
Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)
NCT02014636COMPLETEDPHASE1
42 participants
INTERVENTIONAL
Boston, United States +5 more
Started: Dec 27, 2013
Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients
NCT00158782COMPLETEDPHASE1
75 participants
INTERVENTIONAL
Durham, United States +1 more
Started: Sep 28, 2004
Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer
NCT01064310COMPLETEDPHASE3
169 participants
INTERVENTIONAL
Helsinki, Finland +50 more
Started: May 17, 2010
Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma
NCT00720941COMPLETEDPHASE3
1.11K participants
INTERVENTIONAL
Huntsville, United States +226 more
Started: Aug 14, 2008
Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
NCT01147822COMPLETEDPHASE2
367 participants
INTERVENTIONAL
Guangzhou, China +20 more
Started: May 19, 2010
An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma
NCT00992121COMPLETEDPHASE1
11 participants
INTERVENTIONAL
Cambridge, United Kingdom
Started: Nov 18, 2009
Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors
NCT00516672COMPLETEDPHASE1
30 participants
INTERVENTIONAL
Aichi, Japan +1 more
Started: Sep 10, 2007
Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma
NCT00731211COMPLETEDPHASE2
57 participants
INTERVENTIONAL
San Francisco, United States +16 more
Started: Sep 1, 2008
Neoadjuvant Pazopanib in Renal Cell Carcinoma
NCT01361113COMPLETEDPHASE2
21 participants
INTERVENTIONAL
Chapel Hill, United States +1 more
Started: Jun 1, 2011
Showing 20 of 100 total trials